DNA RNA and Cells

14 Oct 2020 Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
13 Oct 2020 Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
13 Oct 2020 Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program
13 Oct 2020 Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
08 Oct 2020 Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
08 Oct 2020 TIO Bioventures Launches TCRyption Inc., a Novel TCR-T cell based Immunotherapy Company
08 Oct 2020 Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
08 Oct 2020 OliX Pharmaceuticals Announces Expansion of Collaboration with Laboratoires Théa to Develop siRNA Therapeutics for Ophthalmic Diseases
08 Oct 2020 Sensei Biotherapeutics Announces $28.5 Million Financing To Advance Clinical Pipeline and Immunophage™ Platform Targeting Multiple Cancers
08 Oct 2020 Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
07 Oct 2020 Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs
07 Oct 2020 Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment
06 Oct 2020 First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma
06 Oct 2020 AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome
06 Oct 2020 Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS® T Cell Therapy in Hepatocellular Carcinoma
06 Oct 2020 Gamida Cell Announces Positive Topline Data on Secondary Endpoints from Phase 3 Clinical Study of Omidubicel in Patients with Hematologic Malignancies
02 Oct 2020 bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)
02 Oct 2020 Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
02 Oct 2020 Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial
02 Oct 2020 Mesoblast Receives Complete Response Letter From the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
01 Oct 2020 Alnylam Reports Positive Topline Results from ILLUMINATE-B Phase 3 Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 in Children Under the Age of Six
30 Sep 2020 Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
29 Sep 2020 Orgenesis announces agreement to acquire Koligo Therapeutics, a leader in personalized cell therapies
29 Sep 2020 Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy
29 Sep 2020 Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up